Bluejay Diagnostics says SYMON-II pivotal study completes enrollment of 750 patients for Symphony IL-6 test
BJDX•Manufacturing and cash position
Manufacturing readiness moved forward with a U.S. manufacturing contract aimed at reducing supply-chain risk.
Cash totaled $9.6 million at June 30, 2026; management expects funding to last through Q2 2027.
SYMON-II pivotal study completes enrollment
Bluejay Diagnostics reported Q2 2026 progress on its SYMON-II pivotal study for the investigational Symphony IL-6 test.
Targeted enrollment of 750 hospital patients is complete; results have not been presented in the release.
Work continues on validation intended to support a planned FDA 510(k) submission, a key step toward commercialization.
